Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Cancer Treatment Centers of America deploys Intel's personal health system solution

Cancer Treatment Centers of America (CTCA) is deploying the Intel® Health Guide - a next-generation personal health system solution that allows physicians and clinicians to proactively monitor their patients' care at home - as part of its commitment to provide patients with the information and resources they need to make educated decisions about their cancer care.

17 Dec 2010

FDA's decision on Avastin will take away choice for many patients, says Breastcancer.org

Dr. Marisa Weiss, president and founder of Breastcancer.org and a breast oncologist in the Philadelphia area submitted a letter to the U.S. Food and Drug Administration prior to the Oncology Drug Advisory Committee (ODAC) meeting to review data for Avastin's use in metastatic HER2-negative breast cancer. In light of today's news that the FDA has recommended removing Avastin's approval to treat breast cancer, Breastcancer.org is making public Dr. Weiss' ODAC letter in its entirety.

17 Dec 2010

Merck, sanofi-aventis enter global cancer research and development agreement

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Merck, has signed a worldwide research and development agreement with sanofi-aventis U.S. Inc., under which Merck Serono and sanofi-aventis U.S. Inc. will collaboratively investigate novel experimental combinations of agents that could block specific pathways in cancer cells. This collaboration could deliver novel targeted oncology treatments with high therapeutic potential.

17 Dec 2010

Pediatric cancer researchers study medulloblastoma for new treatment

Pediatric cancer researchers at The Children's Hospital of Philadelphia contributed important expertise to a new landmark study of medulloblastoma, a type of brain tumor typically found in children.

17 Dec 2010

Human fetal immune system entirely different from adult immune system

UCSF researchers have shown for the first time that the human fetal immune system arises from an entirely different source than the adult immune system, and is more likely to tolerate than fight foreign substances in its environment.

17 Dec 2010

Alliance announces full year 2011 guidance, reaffirms 2010 financial guidance

Alliance HealthCare Services, Inc., a leading national provider of outpatient diagnostic imaging and radiation therapy services, reaffirmed full year 2010 guidance and announced financial guidance for full year 2011.

17 Dec 2010

Bayer's SAFYRAL oral contraceptive receives FDA approval

Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL raises folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing it.

17 Dec 2010

Recordati, Nymox sign European licensing agreement for BPH investigational drug, NX-1207

Recordati and Nymox Pharmaceutical Corporation announced today the signing of a European licensing agreement for the development and commercialization of NX-1207, Nymox's Phase III investigational drug currently in clinical development in the U.S. for the treatment of benign prostatic hyperplasia (BPH).

17 Dec 2010

High-dose rate brachytherapy procedure to treat prostate cancer

Beaumont Hospital radiation oncologists have launched a research study to treat men with low to intermediate risk prostate cancer with a single dose of radiation.

17 Dec 2010

Scientists decipher genetic code for pediatric medulloblastoma

Scientists at the Johns Hopkins Kimmel Cancer Center have deciphered the genetic code for medulloblastoma, the most common pediatric brain cancer and a leading killer of children with cancer.

16 Dec 2010

FDA issues CRL for AstraZeneca's ticagrelor NDA

AstraZeneca announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for ticagrelor (BRILINTA™).

16 Dec 2010

Genetic breakthrough in lung cancer

For the study the team studied samples of lung tumors and nearby healthy lung tissue from 30 patients and examined the samples for the presence of messenger ribonucleic acid (mRNA) associated with 48 known genes for molecules called nuclear hormone receptors. Then they compared the active genes with patient outcomes and found that the expression of genes for certain nuclear hormone receptors helped predict patient survival.

16 Dec 2010

Liver cancer in cirrhotic patients effectively treated with radiofrequency ablation

Researchers from Italy determined that radiofrequency ablation (RFA) is a safe and effective therapy for managing hepatocellular carcinoma (HCC) in cirrhotic patients. The high repeatability of RFA is advantageous in controlling recurrences of cancerous tumors in the liver. Results of this 10-year retrospective study are available in the January 2011 issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

16 Dec 2010

Some cancers more prevalent in the wealthy

A new report has shown that Australians living in wealthy areas are more likely to get breast, prostate and skin cancers than those living in poorer zones. The report from Australian Institute of Health and Welfare, released yesterday also shows that those living in disadvantaged parts of the country are more likely to have bowel, cervical and lung cancers. Not so much with bowel cancer, but lung cancer incidence varied to a large extent. Main results showed;

16 Dec 2010

NextGen Healthcare announces partnership with Wills Eye for meaningful use

NextGen Healthcare Information Systems, a wholly owned subsidiary of Quality Systems, and leading provider of healthcare information systems and connectivity solutions, today announced an agreement with Wills Eye Health System to deploy NextGen® Ambulatory EHR and NextGen® Practice Management.

16 Dec 2010

UT Southwestern and Rabin Medical Center enter innovative 5-year affiliation agreement

UT Southwestern Medical Center and Rabin Medical Center, Israel, two of the world's top academic medical centers, announced today that they have entered into an innovative affiliation agreement for the next five years.

16 Dec 2010

Combination therapy improves survival rates in patients with advanced non-small cell lung cancer

A combination therapy for treating cancer discovered at the University of Colorado Cancer Center showed improved survival rates in patients with advanced non-small cell lung cancer (NSCLC), according to results from a double-blind, placebo-controlled phase 2 trial run by Syndax Pharmaceuticals.

16 Dec 2010

$Phase 1b clinical trial of JX-594 in metastatic, refractory colorectal cancer commences in Korea$

Phase 1b clinical trial of JX-594 in metastatic, refractory colorectal cancer commences in Korea

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that enrollment and treatment of patients in a Phase 1b clinical trial has been initiated to evaluate JX-594 in patients with advanced metastatic, refractory colorectal cancer (CRC).

16 Dec 2010

New findings says TRIM24 protein plays active role in breast cancer formation

The recently identified TRIM24 protein plays an active role in pushing normal breast cells into rapid cell proliferation and, potentially, into breast cancer.

16 Dec 2010

Enzon in collaboration with NCI initiates EZN-2968, EZN-2208 Phase I studies for arresting tumor growth

Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).

16 Dec 2010

Oncology News and Research

Further Reading

Cancer Treatment Centers of America deploys Intel's personal health system solution

FDA's decision on Avastin will take away choice for many patients, says Breastcancer.org

Merck, sanofi-aventis enter global cancer research and development agreement

Pediatric cancer researchers study medulloblastoma for new treatment

Human fetal immune system entirely different from adult immune system

Alliance announces full year 2011 guidance, reaffirms 2010 financial guidance

Bayer's SAFYRAL oral contraceptive receives FDA approval

Recordati, Nymox sign European licensing agreement for BPH investigational drug, NX-1207

High-dose rate brachytherapy procedure to treat prostate cancer

Scientists decipher genetic code for pediatric medulloblastoma

FDA issues CRL for AstraZeneca's ticagrelor NDA

Genetic breakthrough in lung cancer

Liver cancer in cirrhotic patients effectively treated with radiofrequency ablation

Some cancers more prevalent in the wealthy

NextGen Healthcare announces partnership with Wills Eye for meaningful use

UT Southwestern and Rabin Medical Center enter innovative 5-year affiliation agreement

Combination therapy improves survival rates in patients with advanced non-small cell lung cancer

Phase 1b clinical trial of JX-594 in metastatic, refractory colorectal cancer commences in Korea

New findings says TRIM24 protein plays active role in breast cancer formation

Enzon in collaboration with NCI initiates EZN-2968, EZN-2208 Phase I studies for arresting tumor growth

Cancer Research - Second Edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News